Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

295.07 +3.07 (+1.05%)
Streaming Delayed Price Updated: 2:07 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Amgen

< Previous 1 2 3 4 5 6 7 8 9
...
54 55 Next >
AI Revolutionizes Pharma: Smarter Excipients for Safer, More Potent Drugs
San Francisco, CA – October 31, 2025 – Artificial intelligence (AI) is ushering in a transformative era for the pharmaceutical industry, particularly in the often-overlooked yet critical domain of... 
Via TokenRing AI
Topics Artificial Intelligence Supply Chain
AI: The Pharmaceutical Sector’s New Catalyst for a Healthier Future
The pharmaceutical industry is in the midst of a profound and rapid transformation, driven by the pervasive integration of Artificial Intelligence (AI). What was once a futuristic concept is, by late... 
Via TokenRing AI
Topics Animal Testing Artificial Intelligence Economy
Price Over Earnings Overview: Amgen
 
Via Benzinga
How Royalty Pharma Prints Cash Without Biotech's Biggest Risks
Via MarketBeat
Marjorie Taylor Greene Buys Netflix Stock After Downbeat Q3 Earnings, Expands Big Tech Bet
MTG "buys the dip" on Netflix (NFLX) stock after a bad Q3 report. See all 14 of her new purchases, including MSFT and AMZN. 
Via Benzinga
Marjorie Taylor Greene Buys 6 Stocks: Buffett, Health Care — And This Magnificent 7 Stock
Marjorie Taylor Greene discloses buying more stocks in October. Here's a look at what she added to her portfolio. 
Via Benzinga
S&P 500 Healthcare Sector Navigates Mixed Market Waters on October 29, 2025
On October 29, 2025, the broader market exhibited a decidedly mixed performance, reflecting a prevailing sense of uncertainty among investors. Against this backdrop of fluctuating sentiment, the S&P... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
What Does the Market Think About Amgen Inc?
 
Via Benzinga
2 Value Stocks on Our Watchlist and 1 Facing Headwinds
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued... 
Via StockStory
Topics Artificial Intelligence
Biogen's Immunology Pipeline Has Long-Term Potential: Analyst
Biogen gains exclusive rights to Vanqua's oral C5aR1 antagonist, boosting its immunology pipeline with potential across multiple immune diseases. 
Via Benzinga
1 Top Dividend Growth Stock to Buy Right Now
Its shares might not remain undervalued for that much longer. 
Via The Motley Fool
Topics Economy Government Intellectual Property
Market Minute: Dow Soars, Apple Hits Record High as 20-Day Government Shutdown Fuels Gold Rally
The U.S. financial markets opened the week with a robust performance on October 20, 2025, as the Dow Jones Industrial Average (DJIA) extended its gains, and tech giant Apple Inc. (NASDAQ: AAPL) reached... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
2 Reasons to Like AMGN and 1 to Stay Skeptical
Although Amgen (currently trading at $299.86 per share) has gained 9.6% over the last six months, it has trailed the S&P 500’s 29.3% return during that period. This might have investors contemplating... 
Via StockStory
Topics Stocks
United Therapeutics Forges Ahead with Share Repurchases, Not Dividends, Following July 2025 Volume Surge
In a financial landscape often fixated on consistent dividend payouts, United Therapeutics Corporation (NASDAQ: UTHR) stands out with a distinct capital allocation strategy. Contrary to market... 
Via MarketMinute
Topics Retirement
Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?
Trump's promise to cut cost of Novo Nordisk A/S drug Ozempic from $1,300 to $150 shakes GLP-1 gold rush, with potential impact on Eli Lilly and Pfizer. 
Via Benzinga
Topics Government
Marjorie Taylor Greene, Cathie Wood Snap Up The Same 13 Stocks — Here's the Unlikely Portfolio Crossover
A look at the stock owned by both Ark Funds and Congresswoman Marjorie Taylor Greene. 
Via Benzinga
Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity
William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therapy pipeline. 
Via Benzinga
Dow Jones Stumbles with Fractional Dip, Signaling Cautious Market Sentiment Amidst Global Headwinds
New York, NY – October 15, 2025 – The Dow Jones Industrial Average (DJIA) experienced a fractional dip today, reflecting a palpable sense of caution pervading market sentiment. While other major... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
Reflecting On Therapeutics Stocks’ Q2 Earnings: Amgen (NASDAQ:AMGN)
Looking back on therapeutics stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Amgen (NASDAQ:AMGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
Trump Plans AstraZeneca Deal To Cut Drug Prices For Low-Income Americans
Trump to announce new deal with AstraZeneca to lower prescription drug costs for Americans using most-favored-nation pricing model. 
Via Benzinga
Topics Government
Trump Administration Engages Pharmacies, GoodRx For TrumpRx Launch
Pharmacies and GoodRx are in talks to join TrumpRx, a new drug pricing site aiming to lower prescription costs for U.S. consumers. 
Via Benzinga
Topics Government
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
2 S&P 500 Stocks to Target This Week and 1 Facing Challenges
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some... 
Via StockStory
Topics Stocks
Martin Capital Buys Into Portland General Electric’s Defensive Power Play
Via The Motley Fool
Topics Energy Regulatory Compliance
Amgen To Offer Cholesterol Drug At 60% Discount As Trump Administration's Call To Lower Drug Prices
Amgen launches AmgenNow, offering Repatha at $239 per month, expanding direct access for U.S. patients with no insurer restrictions. 
Via Benzinga
Topics Government
Martin Capital Dumps $3.0 Million Worth of LyondellBasell Industries Stock
Via The Motley Fool
Topics Energy
Martin Capital Liquidates its Diageo Position: What That Means for the Alcoholic Beverages Titan
Via The Motley Fool
Martin Capital Exits $5.8 Million Comcast Stake as Broadband Challenges Persist
Via The Motley Fool
Martin Capital Sells $3.6 Million in JPMorgan Stock — What to Know Ahead of Q3 Earnings
Via The Motley Fool
Amgen To Sell Cholesterol Drug For Approximately 60% Discount
Patients can purchase Repatha at a discount through Amgen’s direct-to-patient program, AmgenNow. 
Via Stocktwits
Topics Government
< Previous 1 2 3 4 5 6 7 8 9
...
54 55 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.